Shares of enGene Holdings Inc. (NASDAQ:ENGNW – Get Free Report) shot up 3.8% on Thursday . The company traded as high as $2.49 and last traded at $2.49. 2,031 shares were traded during trading, a decline of 82% from the average session volume of 11,448 shares. The stock had previously closed at $2.40.
enGene Trading Up 8.4%
The company has a fifty day moving average of $2.35 and a 200-day moving average of $1.34.
About enGene
enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.
Read More
- Five stocks we like better than enGene
- 3 Stocks to Consider Buying in October
- These 3 Banks Are Rallying Into Year-End, But Will It Continue?
- What Are the U.K. Market Holidays? How to Invest and Trade
- 3 Surging Stocks Just Got the Ultimate Stamp of Approval From the S&P 500
- Stock Splits, Do They Really Impact Investors?
- This ETF Caught a Major Tailwind After the Fed’s Rate Cut
Receive News & Ratings for enGene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for enGene and related companies with MarketBeat.com's FREE daily email newsletter.
